Exact Sciences Corporation
EXAS
株式のランク
#1155
Exact Sciences Corporation specializes in developing and distributing cancer... Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers. Within this suite, the Oncotype Test provides detailed tumor profiling from tissue samples, assisting in treatment selection for individuals battling advanced, metastatic, refractory, or recurrent cancers. Furthermore, they offer the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy designed for advanced-stage prostate cancer patients, and Oncomap ExTra, which delivers a comprehensive biological insight into challenging, rare, or aggressive malignancies. Exact Sciences also provides COVID-19 testing services. Future initiatives involve enhancing Cologuard's performance characteristics and pioneering novel blood- and other fluid-based diagnostic tests. The company maintains important license agreements with the MAYO Foundation for Medical Education and Research and Hologic, Inc. Established in 1995, Exact Sciences Corporation's corporate headquarters are located in Madison, Wisconsin.
株価
$104.91
最終同期: 2026-03-23
時価総額
$20.03B
変化（1日）
0.00%
変化（1年）
67.24%
国
US
取引 Exact Sciences Corporation (EXAS)
カテゴリー
Healthcare
Exact Sciences Corporation（EXAS）の発行済株式数
December 2025 時点の発行済株式数 189.74M
Exact Sciences Corporation の最新の財務報告および株価によると、現在の発行済株式数は 189.74M です。December 2024 の終わりには、同社は 184.20M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Exact Sciences Corporation（EXAS）の発行済株式数の履歴（2000 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2026 (TTM) | 189.74M | 0.56% |
| 2025 | 188.69M | 2.44% |
| 2024 | 184.20M | 2.25% |
| 2023 | 180.14M | 2.15% |
| 2022 | 176.35M | 2.92% |
| 2021 | 171.35M | 13.37% |
| 2020 | 151.14M | 15.15% |
| 2019 | 131.26M | 7.41% |
| 2018 | 122.21M | 5.64% |
| 2017 | 115.68M | 13.04% |
| 2016 | 102.34M | 11.07% |
| 2015 | 92.14M | 14.84% |
| 2014 | 80.23M | 18.87% |
| 2013 | 67.49M | 13.47% |
| 2012 | 59.48M | 13.27% |
| 2011 | 52.51M | 29.80% |
| 2010 | 40.46M | 23.37% |
| 2009 | 32.79M | 20.50% |
| 2008 | 27.21M | 0.99% |
| 2007 | 26.95M | 1.64% |
| 2006 | 26.51M | 0.91% |
| 2005 | 26.27M | 3.69% |
| 2004 | 25.33M | 33.96% |
| 2003 | 18.91M | 2.59% |
| 2002 | 18.43M | 11.80% |
| 2001 | 16.49M | 1,027.91% |
| 2000 | 1.46M | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 371.00M | 95.53% |
US
|
|
| 705.30M | 271.72% |
US
|
|
| 143.28M | -24.49% |
US
|
|
| - | - |
CN
|
|
| 282.00M | 48.63% |
US
|
